Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
liraglutide
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes mellitus
- Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide
- HbA1c for diet treated subjects 6.5-12%, both inclusive
- HbA1c for sulphonylurea or repaglinide treated subjects maximum 10%
- Body mass index (BMI) at least 27 kg/m^2
- Euthyroid subjects
- Fasting blood glucose 7-14 mmol/l
Exclusion Criteria:
- Impaired liver function
- Impaired renal function
- Cardiac problems
- Uncontrolled treated/untreated hypertension
- Recurrent severe hypoglycaemia as judged by the Investigator
- Known or suspected allergy to trial product or related products
- Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
Sites / Locations
- Novo Nordisk Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
NNC 90-1170
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change in weight
Secondary Outcome Measures
Total fat mass (assessed by use of DEXA (dual energy X-ray absorptiometry) scan)
Waist circumference
Spontaneous energy intake assessed in connection to the ad libitum lunch meal
Appetite assessed in connection with the fixed breakfast meal (assessed by the use of VAS (visual analogue scale))
Gastric emptying rate
Energy expenditure
HbA1c (Glycosylated Haemoglobin)
Adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01508949
Brief Title
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
Official Title
NNC 90-1170 Mechanism of Action: A Single-centre, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial Evaluating the Effect of NNC 90-1170 on Weight and Appetite in Obese Subjects With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
June 2001 (undefined)
Primary Completion Date
March 2002 (Actual)
Study Completion Date
March 2002 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
NNC 90-1170
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
liraglutide
Other Intervention Name(s)
NNC 90-1170
Intervention Description
Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Primary Outcome Measure Information:
Title
Change in weight
Secondary Outcome Measure Information:
Title
Total fat mass (assessed by use of DEXA (dual energy X-ray absorptiometry) scan)
Title
Waist circumference
Title
Spontaneous energy intake assessed in connection to the ad libitum lunch meal
Title
Appetite assessed in connection with the fixed breakfast meal (assessed by the use of VAS (visual analogue scale))
Title
Gastric emptying rate
Title
Energy expenditure
Title
HbA1c (Glycosylated Haemoglobin)
Title
Adverse events
10. Eligibility
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes mellitus
Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide
HbA1c for diet treated subjects 6.5-12%, both inclusive
HbA1c for sulphonylurea or repaglinide treated subjects maximum 10%
Body mass index (BMI) at least 27 kg/m^2
Euthyroid subjects
Fasting blood glucose 7-14 mmol/l
Exclusion Criteria:
Impaired liver function
Impaired renal function
Cardiac problems
Uncontrolled treated/untreated hypertension
Recurrent severe hypoglycaemia as judged by the Investigator
Known or suspected allergy to trial product or related products
Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Frederiksberg C
ZIP/Postal Code
1958
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
15277417
Citation
Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004 Aug;27(8):1915-21. doi: 10.2337/diacare.27.8.1915.
Results Reference
result
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
We'll reach out to this number within 24 hrs